Zum Hauptinhalt springen

CoQ <subscript>10</subscript> supplementation rescues nephrotic syndrome through normalization of H <subscript>2</subscript> S oxidation pathway.

Kleiner, G ; Barca, E ; et al.
In: Biochimica et biophysica acta. Molecular basis of disease, Jg. 1864 (2018-11-01), Heft 11, S. 3708-3722
Online academicJournal

Titel:
CoQ <subscript>10</subscript> supplementation rescues nephrotic syndrome through normalization of H <subscript>2</subscript> S oxidation pathway.
Autor/in / Beteiligte Person: Kleiner, G ; Barca, E ; Ziosi, M ; Emmanuele, V ; Xu, Y ; Hidalgo-Gutierrez, A ; Qiao, C ; Tadesse, S ; Area-Gomez, E ; Lopez, LC ; Quinzii, CM
Link:
Zeitschrift: Biochimica et biophysica acta. Molecular basis of disease, Jg. 1864 (2018-11-01), Heft 11, S. 3708-3722
Veröffentlichung: Amsterdam : Elsevier, 2018
Medientyp: academicJournal
ISSN: 1879-260X (electronic)
DOI: 10.1016/j.bbadis.2018.09.002
Schlagwort:
  • Alkyl and Aryl Transferases genetics
  • Animals
  • Antioxidants therapeutic use
  • Ataxia complications
  • Ataxia metabolism
  • Disease Models, Animal
  • HeLa Cells
  • Humans
  • Kidney metabolism
  • Kidney pathology
  • Metabolic Networks and Pathways drug effects
  • Mice
  • Mice, Transgenic
  • Mitochondria drug effects
  • Mitochondria metabolism
  • Mitochondrial Diseases complications
  • Mitochondrial Diseases metabolism
  • Muscle Weakness complications
  • Muscle Weakness metabolism
  • Nephrotic Syndrome etiology
  • Nephrotic Syndrome metabolism
  • Nephrotic Syndrome pathology
  • Oxidation-Reduction drug effects
  • Oxidative Stress drug effects
  • Oxidoreductases Acting on Sulfur Group Donors genetics
  • Oxidoreductases Acting on Sulfur Group Donors metabolism
  • Reactive Oxygen Species metabolism
  • Ubiquinone metabolism
  • Ubiquinone pharmacology
  • Ubiquinone therapeutic use
  • Antioxidants pharmacology
  • Ataxia drug therapy
  • Hydrogen Sulfide metabolism
  • Mitochondrial Diseases drug therapy
  • Muscle Weakness drug therapy
  • Nephrotic Syndrome drug therapy
  • Ubiquinone analogs & derivatives
  • Ubiquinone deficiency
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Research Support, N.I.H., Extramural
  • Language: English
  • [Biochim Biophys Acta Mol Basis Dis] 2018 Nov; Vol. 1864 (11), pp. 3708-3722. <i>Date of Electronic Publication: </i>2018 Sep 06.
  • MeSH Terms: Antioxidants / *pharmacology ; Ataxia / *drug therapy ; Hydrogen Sulfide / *metabolism ; Mitochondrial Diseases / *drug therapy ; Muscle Weakness / *drug therapy ; Nephrotic Syndrome / *drug therapy ; Ubiquinone / *analogs & derivatives ; Ubiquinone / *deficiency ; Alkyl and Aryl Transferases / genetics ; Animals ; Antioxidants / therapeutic use ; Ataxia / complications ; Ataxia / metabolism ; Disease Models, Animal ; HeLa Cells ; Humans ; Kidney / metabolism ; Kidney / pathology ; Metabolic Networks and Pathways / drug effects ; Mice ; Mice, Transgenic ; Mitochondria / drug effects ; Mitochondria / metabolism ; Mitochondrial Diseases / complications ; Mitochondrial Diseases / metabolism ; Muscle Weakness / complications ; Muscle Weakness / metabolism ; Nephrotic Syndrome / etiology ; Nephrotic Syndrome / metabolism ; Nephrotic Syndrome / pathology ; Oxidation-Reduction / drug effects ; Oxidative Stress / drug effects ; Oxidoreductases Acting on Sulfur Group Donors / genetics ; Oxidoreductases Acting on Sulfur Group Donors / metabolism ; Reactive Oxygen Species / metabolism ; Ubiquinone / metabolism ; Ubiquinone / pharmacology ; Ubiquinone / therapeutic use
  • References: Electrophoresis. 2007 Nov;28(21):3811-20. (PMID: 17960833) ; Biofactors. 2003;18(1-4):11-22. (PMID: 14695916) ; EMBO Mol Med. 2017 Jan;9(1):96-111. (PMID: 27856618) ; Nat Med. 2009 Feb;15(2):200-5. (PMID: 19136963) ; Nat Med. 2010 Aug;16(8):869-71. (PMID: 20657580) ; Am J Hum Genet. 2006 Dec;79(6):1125-9. (PMID: 17186472) ; Sci Signal. 2009 Nov 10;2(96):ra72. (PMID: 19903941) ; J Pharmacol Exp Ther. 1996 Apr;277(1):150-5. (PMID: 8613912) ; Mol Microbiol. 2004 Aug;53(4):1147-60. (PMID: 15306018) ; Biochim Biophys Acta. 2014 Jul;1842(7):893-901. (PMID: 24576561) ; Clin Genet. 2017 Aug;92(2):224-226. (PMID: 28044327) ; J Am Soc Nephrol. 2007 Oct;18(10):2773-80. (PMID: 17855635) ; FASEB J. 2013 Feb;27(2):612-21. (PMID: 23150520) ; J Nutr. 1995 Mar;125(3):446-53. (PMID: 7876919) ; FASEB J. 2008 Jun;22(6):1874-85. (PMID: 18230681) ; Front Mol Neurosci. 2017 Oct 24;10:342. (PMID: 29114206) ; Int J Biochem Cell Biol. 2008;40(8):1543-54. (PMID: 18207445) ; J Biol Chem. 2003 Nov 28;278(48):47449-58. (PMID: 14506246) ; Front Mol Biosci. 2017 Dec 04;4:82. (PMID: 29255714) ; Am J Nephrol. 2005 Nov-Dec;25(6):604-10. (PMID: 16282678) ; Antioxid Redox Signal. 2011 Jul 15;15(2):379-91. (PMID: 21028947) ; Front Mol Biosci. 2018 Jun 12;5:55. (PMID: 29946548) ; Sci Rep. 2016 Feb 15;6:20831. (PMID: 26877209) ; J Child Neurol. 2013 Mar;28(3):404-8. (PMID: 23307888) ; Trends Cell Biol. 2016 May;26(5):367-378. (PMID: 26827090) ; Biofactors. 2008;32(1-4):31-9. (PMID: 19096098) ; Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12474-9. (PMID: 23836652) ; Nat Commun. 2013;4:1366. (PMID: 23340406) ; Diabetes. 2012 Oct;61(10):2575-84. (PMID: 22688335) ; Cerebellum. 2007;6(2):118-22. (PMID: 17510911) ; Free Radic Biol Med. 2016 Nov;100:5-13. (PMID: 27105951) ; Mol Cell. 2008 Nov 21;32(4):529-39. (PMID: 19026783) ; Arch Neurol. 2012 Aug;69(8):978-83. (PMID: 22490322) ; Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1795-7. (PMID: 25142877) ; Kidney Int. 2004 Jul;66(1):20-8. (PMID: 15200409) ; Front Physiol. 2017 Jul 25;8:525. (PMID: 28790927) ; Free Radic Biol Med. 2006 Feb 1;40(3):480-7. (PMID: 16443163) ; J Biol Chem. 2012 Jan 20;287(4):2678-88. (PMID: 22134919) ; Biochem J. 1996 Jan 1;313 ( Pt 1):327-34. (PMID: 8546703) ; EMBO Mol Med. 2017 Jan;9(1):78-95. (PMID: 27856619) ; Drug Metab Rev. 2006;38(4):733-44. (PMID: 17145698) ; Eur J Hum Genet. 2015 Sep;23(9):1254-8. (PMID: 25564041) ; J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S443-53. (PMID: 20978941) ; J Med Genet. 1971 Mar;8(1):41-8. (PMID: 5098070) ; J Clin Invest. 2011 May;121(5):2013-24. (PMID: 21540551) ; Redox Biol. 2015;4:289-95. (PMID: 25625583) ; Am J Kidney Dis. 2017 Jul;70(1):139-144. (PMID: 28117207) ; Autophagy. 2009 Jan;5(1):19-32. (PMID: 19115482) ; Essays Biochem. 2018 Jul 20;62(3):235-254. (PMID: 30030360) ; Cell Metab. 2016 Apr 12;23(4):725-34. (PMID: 27076081) ; Arch Biochem Biophys. 1996 Jun 15;330(2):395-400. (PMID: 8660670) ; FASEB J. 2011 Aug;25(8):2669-87. (PMID: 21551238) ; Can J Biochem Physiol. 1959 Aug;37(8):911-7. (PMID: 13671378) ; Biochim Biophys Acta. 2009 May;1787(5):384-92. (PMID: 19059197) ; Hum Mol Genet. 2013 Dec 1;22(23):4768-83. (PMID: 23847050) ; Free Radic Biol Med. 2003 Mar 1;34(5):563-75. (PMID: 12614845) ; Mol Syndromol. 2014 Jul;5(3-4):163-9. (PMID: 25126049) ; Mol Syndromol. 2014 Jul;5(3-4):119-40. (PMID: 25126045) ; J Clin Invest. 2013 Dec;123(12):5179-89. (PMID: 24270420) ; Am J Physiol Renal Physiol. 2008 Nov;295(5):F1535-44. (PMID: 18784258) ; EMBO Mol Med. 2011 Jul;3(7):410-27. (PMID: 21567994) ; Trends Biochem Sci. 2017 Oct;42(10):824-843. (PMID: 28927698) ; Neurobiol Dis. 2012 Jan;45(1):219-33. (PMID: 21871565) ; PLoS One. 2010 Jul 30;5(7):e11897. (PMID: 20689595) ; PLoS One. 2012;7(2):e30606. (PMID: 22359546) ; Biochem Pharmacol. 2018 Mar;149:29-41. (PMID: 29225129) ; Biochim Biophys Acta. 1983 Sep 13;759(3):286-91. (PMID: 6882805) ; Biochem Pharmacol. 2018 Mar;149:77-90. (PMID: 29248597) ; J Am Soc Nephrol. 2005 Oct;16(10):2847-51. (PMID: 16120817) ; FASEB J. 2010 Oct;24(10):3733-43. (PMID: 20495179) ; Biochim Biophys Acta. 2016 Aug;1857(8):1079-1085. (PMID: 27060254) ; Medicine (Baltimore). 2017 Nov;96(47):e8880. (PMID: 29382012) ; Nephrol Ther. 2017 Apr;13 Suppl 1:S23-S28. (PMID: 28577739) ; PLoS Genet. 2008 Apr 25;4(4):e1000061. (PMID: 18437205) ; EMBO Mol Med. 2015 Mar 23;7(5):670-87. (PMID: 25802402) ; Mol Cell Proteomics. 2007 Jul;6(7):1215-25. (PMID: 17426019) ; Nat Rev Nephrol. 2016 May;12(5):267-80. (PMID: 26804019) ; Hum Mol Genet. 2013 Mar 15;22(6):1233-48. (PMID: 23255162) ; Neuropediatrics. 2007 Apr;38(2):78-82. (PMID: 17712735)
  • Grant Information: UL1TR001873 United States NH NIH HHS; P01 HD080642 United States HD NICHD NIH HHS; K01 AG045335 United States AG NIA NIH HHS; UL1 TR001873 United States TR NCATS NIH HHS; P01 HD080642-01 United States NH NIH HHS; U54 NS078059 United States NS NINDS NIH HHS; R01 AG056387 United States AG NIA NIH HHS
  • Contributed Indexing: Keywords: CoQ deficiency; Coenzyme Q(10); Mitochondria; Oxidative stress; Sulfides
  • Substance Nomenclature: 0 (Antioxidants) ; 0 (Reactive Oxygen Species) ; 1339-63-5 (Ubiquinone) ; EC 1.8.- (Oxidoreductases Acting on Sulfur Group Donors) ; EC 1.8.5.- (SQOR protein, human) ; EC 2.5.- (Alkyl and Aryl Transferases) ; EC 2.5.1.- (prenyl diphosphate synthase subunit 2, mouse) ; EJ27X76M46 (coenzyme Q10) ; HB6PN45W4J (idebenone) ; YY9FVM7NSN (Hydrogen Sulfide)
  • SCR Disease Name: Coenzyme Q10 Deficiency
  • Entry Date(s): Date Created: 20180926 Date Completed: 20181211 Latest Revision: 20220716
  • Update Code: 20231215
  • PubMed Central ID: PMC6181133

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -